Strategic Communication for Hormonal Contraception and HIV: An Evidence Review
Source
Johns Hopkins University Center for Communication ProgramsThis article developed by Breakthrough ACTION provides an overview of the evidence to date guiding communication around the potential risks of HIV acquisition associated with progestogen-only injectables, and the background to the development of the Strategic Communication Framework for Hormonal Contraceptive Methods and Potential HIV-Related Risks.
- Strategic Communication Framework for Hormonal Contraceptive Methods and Potential HIV-Related Risks
- Contraception and HIV: What Do the Evidence and WHO Technical Statement Mean for Programs?
- Hormonal Contraceptive Eligibility for Women at High Risk of HIV: Guidance Statement
- Family Planning and HIV Service Integration E-Learning Course
- Hormonal Contraception and HIV: Putting New Developments in Context
- Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study
- Hormonal Contraception and HIV- Technical Update
- Social Franchising: Improving Quality and Expanding Contraceptive Choice in the Private Sector
- Hormonal Contraception and HIV- Webinar
- The ECHO Study Report
- Adaptation of Hormonal Contraceptive and HIV Communication Strategy in Malawi
- Hormonal Contraceptives and HIV – An Introductory Fact Sheet
- Data Scoping Evidence for Contraceptive Use, ANC, Institutional Delivery, SBA, in Nepal
- Hormonal Contraception and Potential HIV Risks- Frequently Asked Questions
- Is Contraceptive Self-injection Cost-effective Compared to Contraceptive Injections from Facility-Based health Workers? Evidence from Uganda
Last Updated
March 25, 2019
